The company's handheld devices are incorporated in strategic CBRN stockpiles 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announced that its devices for rapid chemical detection at the point of need are being included in strategic stockpiles within Europe as part of rescEU, an EU-funded project that is establishing a reserve of disaster response capabilities. These reserves include stockpiles of chemical, biological, radiation and nuclear (CBRN) capabilities for detection, sampling, identification and monitoring due to unintentional disasters or intentional attacks. Over the past six months, the Company has shipped 108 devices to Europ

Multiple handheld MX908 devices will be deployed to detect, identify and mitigate illicit drugs like fentanyl, protecting communities amid the opioid crisis 908 Devices Inc. (NASDAQ:MASS), a pioneer in purpose-built handheld devices for chemical analysis, announces a $2M order from the Texas Department of Public Safety for its MX908 handheld mass spectrometry device. This investment in advanced tools for drug detection builds on an initial order placed last year for several MX908 devices, and is funded through the Community Oriented Policing Services (COPS) grant, a federally funded, state-administered program. The MX908 provides first responders with fast, actionable information when dea

At least 55% reported revenue growth from continuing operations compared to prior year 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial results for the quarter ended March 31, 2025. Preliminary unaudited revenue from continuing operations for the first quarter of 2025 is expected to be at least $11.5 million, compared to $7.4 million of revenue from continuing operations in the first quarter of 2024, reflecting reported growth of approximately 55%. First quarter revenues do not include approximately $1.1 million of additional re

908 Devices Inc. (NASDAQ:MASS), a pioneer in purpose-built handheld devices for chemical analysis, announces that it has received a $1.7 million order from the Ministry of Health of Ukraine for its MX908 handheld mass spectrometry device with Aero module for priority shipment in the first quarter 2025. The devices will be part of an environmental testing kit in a post-war environment and will be used primarily to detect and identify trace substances of hazardous materials, including explosives. The MX908 handheld device utilizes the company's proprietary High Pressure Mass Spectrometry (HPMS) technology to detect and identify hazardous substances including chemical agents, explosives, and

Divested desktop portfolio to Repligen for $70 million, including the MAVEN, MAVERICK, REBEL and ZipChip products Fourth quarter 2024 revenue increases 31% and full year 2024 revenue increases 19% compared to prior year Initiates revenue outlook for 2025 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter and full year ended December 31, 2024. Strategic Transformation Realized 908 Devices cements its unique position as a market-leading provider of analytical tools for tackling critical public health and safety crises through the divestiture of its bioprocessing desktop assets to

WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (NASDAQ:MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for vital health and safety applications. The addition of these desktop assets complements and strengthens Repligen's differentiated PAT portfolio that provides its bioph

908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced it will participate in the following investor conferences. TD Cowen 45th Annual Healthcare Conference, Boston, MA Fireside chat on Wednesday, March 5 at 9:50 a.m. Eastern Time Leerink Global Healthcare Conference, Miami, FL Fireside chat on Tuesday, March 11 at 1 p.m. Eastern Time Interested parties may access a live and archived webcast of these sessions on the "Investors" section of the company website at: www.908devices.com. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing l

908 Devices Inc. (NASDAQ:MASS), a pioneer of handheld and desktop devices for chemical analysis, today announced it will report financial results for the fourth quarter and full year 2024 before market open on Tuesday, March 4, 2025. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event. About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life

Full year 2024 reported revenue growth of at least 15% compared to 2023 908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced preliminary unaudited financial results for the quarter and full year ended December 31, 2024. Preliminary unaudited revenue for the fourth quarter of 2024 is expected to be approximately $17.2 million, compared to $14.4 million in the fourth quarter of 2023, reflecting reported growth of approximately 20%. Fourth quarter handheld revenues grew double digits on a year-over-year basis and desktop revenues grew double digits on both a year-over-year and sequential basis. Preliminary unaudite

Today, 908 Devices Inc. (NASDAQ:MASS) and Getinge announce their collaboration to integrate Getinge's bioreactors with 908 Devices' MAVEN for automated control of glucose and lactate levels in cell cultures. The combined solution will help scientists measure critical process parameters in bioreactors, offering continuous, real-time analysis without the need for manual sampling. In the field of bioprocessing, the continuous monitoring of glucose and lactate levels is crucial for optimizing cell culture conditions and thereby the research and development of biopharmaceutical products. Accurate measurement of these parameters allows for better control of the bioreactor environment, leading t

4 - 908 Devices Inc. (0001555279) (Issuer)

4 - 908 Devices Inc. (0001555279) (Issuer)

4 - 908 Devices Inc. (0001555279) (Issuer)

4 - 908 Devices Inc. (0001555279) (Issuer)

4 - 908 Devices Inc. (0001555279) (Issuer)

SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

SC 13G - 908 Devices Inc. (0001555279) (Subject)

SC 13G - 908 Devices Inc. (0001555279) (Subject)

SC 13G - 908 Devices Inc. (0001555279) (Subject)

SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

DEFA14A - 908 Devices Inc. (0001555279) (Filer)

DEF 14A - 908 Devices Inc. (0001555279) (Filer)

SCHEDULE 13G - 908 Devices Inc. (0001555279) (Subject)

8-K/A - 908 Devices Inc. (0001555279) (Filer)

S-8 - 908 Devices Inc. (0001555279) (Filer)

10-K - 908 Devices Inc. (0001555279) (Filer)

8-K - 908 Devices Inc. (0001555279) (Filer)

8-K - 908 Devices Inc. (0001555279) (Filer)

SCHEDULE 13G/A - 908 Devices Inc. (0001555279) (Subject)

10-Q - 908 Devices Inc. (0001555279) (Filer)

908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Administration (DEA), to serve on its Board of Directors effective immediately. Ms. Leonhart brings a deep understanding of our customers in law enforcement and adjacent markets. Her 34-year career in the DEA encompassed various positions with increasing levels of responsibility, including Special Agent in Charge of the Los Angeles Field Division from 1998 to 2003, Deputy Administrator (nominated by President Bush) from 2003 to 2007, Acting Administrator from 2007 to 2010, and Admini

908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Tony J. Hunt, President and CEO, Repligen Corporation (NASDAQ:RGEN), to serve on its Board of Directors effective immediately. Mr. Hunt brings a deep understanding of the bioprocessing market, with more than 20 years of life sciences management experience. He joined Repligen in 2014 as Chief Operating Officer and was promoted to his current role a year later. Mr. Hunt previously was President of Bioproduction at Life Technologies, which was acquired by Thermo Fisher Scientific in 2014. From 2000 to 2008, he was with Applied Biosystems as

Company appoints six new members to SAB to maximize the company's impact in the proteomics domain 908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the forthcoming appointment of six new individuals to its Scientific Advisory Board (SAB), including Prof. Ileana Cristea, Prof. Jennifer E. Van Eyk, Prof. Anne-Claude Gingras, Prof. Jesper Olsen, Prof. Renã Robinson, and Prof. John Yates. The new SAB members join the board's co-chairs, Christopher D. Brown, CTO 908 Devices; and J. Michael Ramsey, Scientific Founder of 908 Devices and Professor at UNC Chapel Hill, and existing members Prof. Jarrod

Company Appoints Six New Members to its Scientific Advisory Board 908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the forthcoming appointment of six new individuals to its Scientific Advisory Board (SAB), including Professor Michael Betenbaugh, Dr. Tim Charlebois, Dr. Elena Chernokalskaya, Dr. John Erickson, Professor Krishnedndu Roy and Dr. Gene Schaefer. The new SAB members join the board's co-chairs Christopher D. Brown, CTO of 908 Devices, and J. Michael Ramsey, Scientific Founder of 908 Devices and Professor at UNC Chapel Hill. "We are honored to be welcoming Michael, Tim, Elena, John

Experienced HR executive with global tech background joins executive leadership team 908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced that Michele Fournier has joined the company as Chief People Officer. Bringing more than thirty years of global human resources experience in corporate and consulting roles, Michele will lead human resource strategies, processes, and systems to optimize business and talent outcomes for 908 Devices. In this new role, Michele will build a strong talent acquisition pipeline, promote inclusion and diversity in the workplace, and help shape and define employee car

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it has appointed Jeff George and Fenel Eloi to serve on its Board of Directors, effective immediately. Mr. George brings more than two decades of global healthcare and corporate leadership experience across North America, Europe, and emerging markets. He served as the global division head and CEO of two $10 billion divisions of Novartis, Sandoz and Alcon, between 2008 and 2016, where in parallel he served on the Novartis Group executive committee. He also serves on the board of directors of Amneal Pharm

BOSTON--(BUSINESS WIRE)--908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the appointment of industry veteran Steve Davenport as Vice President of Commercial Sales. Contributing to the record number of life sciences companies that went public in 2020, 908 Devices is now executing on its vision by bolstering the leadership team as it builds out channels to reach and serve bioprocess customers. “The bioprocessing market is an exciting growth area for us as our products help biologists and researchers accelerate therapeutic development,” said Dr. Kevin J. Knopp, CEO of 908 Devices. “H

3 - 908 Devices Inc. (0001555279) (Issuer)

4 - 908 Devices Inc. (0001555279) (Issuer)

4 - 908 Devices Inc. (0001555279) (Issuer)

4 - 908 Devices Inc. (0001555279) (Issuer)

4 - 908 Devices Inc. (0001555279) (Issuer)

4 - 908 Devices Inc. (0001555279) (Issuer)

4 - 908 Devices Inc. (0001555279) (Issuer)

4 - 908 Devices Inc. (0001555279) (Issuer)

4 - 908 Devices Inc. (0001555279) (Issuer)

4 - 908 Devices Inc. (0001555279) (Issuer)

Leerink Partners downgraded 908 Devices from Outperform to Market Perform and set a new price target of $4.00 from $12.00 previously

Stephens initiated coverage of 908 Devices with a rating of Overweight and set a new price target of $14.00

SVB Leerink reiterated coverage of 908 Devices with a rating of Outperform and set a new price target of $30.00 from $40.00 previously

Cowen resumed coverage of 908 Devices with a rating of Outperform

SVB Leerink reiterated coverage of 908 Devices with a rating of Outperform and set a new price target of $65.00 from $70.00 previously